fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C‐07 J. Clin. Oncol. 25: 2198–2204.
9 9 Krook, J.E., Moertel, C.G., Gunderson, L.L. et al. (1991). Effective surgical adjuvant therapy for high‐risk rectal carcinoma.N. Engl. J.Med. 324: 709–715.
10 10 Petersen, S.H., Harling, H., Kirkeby, L.T. et al. (2012). Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst. Rev. 3: CD004078.
11 11 Hong, Y.S., Nam, B.‐H., Kim, K.‐P. et al. (2014). Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open‐label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 15: 1245–1253.
12 12 Sainato, A., Cernusco Luna Nunzia, V., Valentini, V. et al. (2014). No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I‐CNR‐RT). Radiother. Oncol. J. 113: 223–229.
13 13 Glynne‐Jones, R., Counsell, N., Quirke, P. et al. (2014). Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann. Oncol. 25: 1356–1362.
14 14 Breugom, A.J., van Gijn, W., Muller, E.W. et al. (2015). Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann. Oncol. Off. 26: 696–701.
15 15 Bosset, J.‐F., Calais, G., Mineur, L. et al. (2014). Fluorouracil‐based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long‐term results of the EORTC 22921 randomised study. Lancet Oncol. 15: 184–190.
16 16 Biagi, J.J., Raphael, M.J., Mackillop, W.J. et al. (2011). Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta‐analysis. JAMA 305: 2335–2342.
17 17 Martin, S.T., Heneghan, H.M., and Winter, D.C. (2012). Systematic review and meta‐analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br. J.Surg. 99: 918–928.
18 18 Kenis, C., Decoster, L., Van Puyvelde, K. et al. (2014). Performance of two geriatric screening tools in older patients with cancer. J. Clin. Oncol. 32: 19–26.
19 19 Maas, M., Nelemans, P.J., Valentini, V. et al. (2010). Long‐term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 11: 835–844.
20 20 Kalady, M.F., de Campos‐Lobato, L.F., Stocchi, L. et al. (2009). Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann. Surg. 250: 582–589.
21 21 Tulchinsky, H., Shmueli, E., Figer, A. et al. (2008). An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease‐free survival in patients with locally advanced rectal cancer. Ann. Surg. Oncol. 15: 2661–2667.
22 22 Ryan, É.J., O’Sullivan, D.P., Kelly, M.E. et al. (2019). Meta‐analysis of the effect of extending the interval after long‐course chemoradiotherapy before surgery in locally advanced rectal cancer. Br. J. Surg. 106: 1298–1310.
23 23 Lefevre, J.H., Mineur, L., Kotti, S. et al. (2016). Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR‐6) J. Clin. Oncol. 34: 3773–3780.
24 24 Perez, K., Safran, H., Sikov, W. et al. (2017). Complete neoadjuvant treatment for rectal cancer: the Brown University Oncology Group CONTRE study. Am. J. Clin. Oncol. 40: 283–287.
25 25 Garcia‐Aguilar, J., Chow, O.S., Smith, D.D. et al. (2015). Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 16: 957–966.
26 26 Fernandez‐Martos, C., Garcia‐Albeniz, X., Pericay, C. et al. (2015). Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long‐term results of the Spanish GCR‐3 phase II randomized trial. Ann. Oncol. 26: 1722–1728.
27 27 Hardiman, K.M., Antunez, A.G., Kanters, A. et al. (2019). Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally‐advanced rectal cancer. J. Surg. Oncol. 120: 308–315.
28 28 Zaborowski, A., Stakelum, A., and Winter, D.C. (2019). Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer. Br. J. Surg. 106: 979–987.
29 29 Petrelli, F., Trevisan, F., Cabiddu, M. et al. (2020). Total neoadjuvant therapy in rectal cancer: a systematic review and meta‐analysis of treatment outcomes. Ann. Surg. 271: 440–448.
30 30 Hospers, G., Bahadoer, R.R., Dijkstra, E.A. et al. (2020). Short‐course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: the randomized RAPIDO trial. J. Clin. Oncol. 38: 4006.
31 31 Conroy, T., Lamfichekh, N., Etienne, P.‐L. et al. (2020). Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J. Clin. Oncol. 38: 4007.
32 32 Marco, M.R., Zhou, L., Patil, S. et al. (2018). Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis. Colon Rectum 61: 1146–1155.
33 33 Markovina, S., Youssef, F., Roy, A. et al. (2017). Improved metastasis‐ and disease‐free survival with preoperative sequential short‐course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long‐course chemoradiotherapy: results of a matched pair analysis. Int. J. Radiat. Oncol. Biol. Phys. 99: 417–426.
34 34 Zheng, R., Lian, S., Huang, X. et al. (2019). The survival benefit of intensified full‐dose XELOX chemotherapy concomitant to radiotherapy and then resting‐period consolidation chemotherapy in locally advanced rectal cancer. J. Cancer 10: 730–736.
35 35 Ciseł, B., Pietrzak, L., Michalski, W. et al. (2019). Long‐course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long‐term results of the randomized Polish II study. Ann. Oncol. 30: 1298–1303.
36 36 Zampino, M.G., Magni, E., Leonardi, M.C. et al. (2009). Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 75: 421–427.
37 37 Yu, X., Wang, Q., Xiao, W. et al. (2018). Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single‐institute phase II study. Cancer Commun. 38: 24.
38 38 CLC, B., Lunniss, P.J., Knowles, C.H. et al. (2012). Anterior resection syndrome. Lancet Oncol. 13: e403–e408.
39 39 EHA, P., Palmer, G.J., Juul, T. et al. (2019). Low anterior resection syndrome and quality of life after sphincter‐sparing rectal cancer surgery: a long‐term longitudinal follow‐up. Dis. Colon Rectum 62: 14–20.
40 40 van Heinsbergen, M., Janssen‐Heijnen, M.L., Leijtens, J.W. et al. (2018). Bowel dysfunction after sigmoid resection underestimated: multicentre study on quality of life after surgery for carcinoma of the rectum and sigmoid. Eur. J. Surg. Oncol. 44: 1261–1267.
41 41 van der Valk, M.J.M., Hilling, D.E., Bastiaannet, E. et al. (2018). Long‐term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 391: 2537–2545.
42 42 Cercek, A., CSD, R., Strombom, P. et al. (2018). Adoption of total neoadjuvant therapy for locally advanced